- Home
- SRZN vs IRD Comparison
SRZN vs IRD Comparison
Compare SRZN & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- IRD
- Stock Information
- Founded
- SRZN 2015
- IRD 2018
- Country
- SRZN United States
- IRD United States
- Employees
- SRZN N/A
- IRD N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- IRD
- Sector
- SRZN Health Care
- IRD
- Exchange
- SRZN Nasdaq
- IRD NYSE
- Market Cap
- SRZN 72.8M
- IRD 62.0M
- IPO Year
- SRZN N/A
- IRD N/A
- Fundamental
- Price
- SRZN $10.00
- IRD $0.95
- Analyst Decision
- SRZN Strong Buy
- IRD Strong Buy
- Analyst Count
- SRZN 2
- IRD 3
- Target Price
- SRZN $38.50
- IRD $6.33
- AVG Volume (30 Days)
- SRZN 15.0K
- IRD 2.4M
- Earning Date
- SRZN 08-11-2025
- IRD 08-15-2025
- Dividend Yield
- SRZN N/A
- IRD N/A
- EPS Growth
- SRZN N/A
- IRD N/A
- EPS
- SRZN N/A
- IRD N/A
- Revenue
- SRZN $11,638,000.00
- IRD $13,651,000.00
- Revenue This Year
- SRZN N/A
- IRD $51.41
- Revenue Next Year
- SRZN N/A
- IRD $68.84
- P/E Ratio
- SRZN N/A
- IRD N/A
- Revenue Growth
- SRZN N/A
- IRD N/A
- 52 Week Low
- SRZN $5.90
- IRD $0.65
- 52 Week High
- SRZN $18.17
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- SRZN 61.67
- IRD N/A
- Support Level
- SRZN $9.15
- IRD N/A
- Resistance Level
- SRZN $10.05
- IRD N/A
- Average True Range (ATR)
- SRZN 0.53
- IRD 0.00
- MACD
- SRZN 0.20
- IRD 0.00
- Stochastic Oscillator
- SRZN 93.33
- IRD 0.00
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.